Ameriprise
VYGR icon

Ameriprise’s Voyager Therapeutics VYGR Stock Holding History

Ameriprise’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-22,435
Closed -$75.8K – 4140
2025
Q1 		$75.8K Buy
+22,435
New +$105K ﹤0.01% 3911
2020
Q3 		– Sell
-123,509
Closed -$1.56M – 3794
2020
Q2 		$1.56M Buy
123,509
+28,101
+29% +$327K ﹤0.01% 2722
2020
Q1 		$873K Buy
95,408
+520
+0.5% +$5.97K ﹤0.01% 2879
2019
Q4 		$1.32M Buy
+94,888
New +$1.38M ﹤0.01% 2940

Other funds holding VYGR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise's VYGR Position: Q2 2025 in Review

Ameriprise sold out of Voyager Therapeutics (VYGR) in Q2 2025, closing a stake of 22,435 shares — an estimated $75.8K sold.

Ameriprise first reported a position in VYGR in Q4 2019 and held it in 4 quarters. The position peaked at $1.56M in Q2 2020. 112 funds tracked by Wall St. Rank hold VYGR as of Q2 2025.

  • Ameriprise reported no remaining Voyager Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Ameriprise sold 22,435 Voyager Therapeutics shares in Q2 2025, an estimated $75.8K.
  • Ameriprise first reported a position in Voyager Therapeutics in Q4 2019 and held it in 4 quarters.
  • Ameriprise's Voyager Therapeutics position peaked at $1.56M in Q2 2020.
  • 112 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q2 2025.

Based on Ameriprise's 13F filing for Q2 2025, filed 14 Aug 2025.